Ticker

TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's…

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancer Durable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol…

Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) is expected to be posting its results before the market opens on Monday, March 30th. Analysts expect Allarity Therapeutics to post earnings of ($0.22) per share for the quarter. Allarity Therapeutics Price Performance ALLR stock opened at $1.08 on Monday. The business has a 50-day moving average price

Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 227,623 shares, a decline of 20.7% from the February 12th total of 287,071 shares. Currently, 1.4% of the company's shares are short sold.

Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to…